About Vakzine Projekt Management
VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.
The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.
News & Press
VPM attends the TBVI Annual Meeting
VPM will present the latest data on the novel tuberculosis vaccine – VPM1002 at the Tuberculosis Vaccine Initiative Partner Meeting from 3 – 6 April 2023 in Les Diablerets, Switzerland
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
We are pleased to announce the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met. Click here for more information.
Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases
The course of respiratory infectious disease pandemics, will strongly depend on how quickly medications or specific vaccines against the pathogens are available. Researchers wanted to investigate in a phase III trial whether the vaccine candidate VPM1002 is also protective against an infection with the novel SARS-CoV-2. The large-scale study has been carried out at several hospitals in Germany and included older people that are susceptible to severe course of the disease. Read about the results here!
Consulting and services
Speed up your development processes by using our expertise. We offer a comprehensive service portfolio covering all stages of pharmaceutical development.
Translational project management from the laboratory bench to clinical development.